Charles River Laboratories International, Inc.’s Stock Price Drops to 150.52 USD, Experiencing a 3.23% Decrease

Charles River Laboratories International, Inc. (CRL)

150.52 USD -5.03 (-3.23%) Volume: 1.36M

Charles River Laboratories International, Inc.’s stock price currently stands at 150.52 USD, experiencing a dip of -3.23% this trading session with a trading volume of 1.36M, reflecting a YTD percentage change of -18.46%, indicating a challenging market performance for CRL.

Latest developments on Charles River Laboratories International, Inc.

Today, Charles River Laboratories International, Inc. (NYSE:CRL) saw fluctuations in its stock price as Mawer Investment Management Ltd. purchased 5,769 shares. Baird adjusted the price target for Charles River Laboratories International to $155 from $173 while maintaining a neutral rating. Additionally, Charles River and Valo Health’s Logica collaboration identified a new Lupus drug candidate, impacting the company’s stock outlook. Despite hitting a 52-week low at $150.19, the question remains whether Wall Street is bullish or bearish on Charles River Laboratories‘ future performance.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Charles River Laboratories has a mixed long-term outlook. While the company scores high in momentum, indicating strong market performance, its scores for value, growth, resilience, and dividend are more moderate. This suggests that while Charles River Laboratories is currently showing positive momentum, investors may want to consider other factors before making long-term investment decisions.

Charles River Laboratories International, Inc. is a company that provides research tools and support services for drug discovery and development. They specialize in supplying animal research models for pharmaceutical and biotechnology companies, hospitals, and academic institutions. With a varied score across different factors, investors should carefully assess the overall outlook of the company before making any investment decisions.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma